Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4590542
Max Phase: Preclinical
Molecular Formula: C89H132N12O28S
Molecular Weight: 1850.16
Molecule Type: Unknown
Associated Items:
ID: ALA4590542
Max Phase: Preclinical
Molecular Formula: C89H132N12O28S
Molecular Weight: 1850.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1ccc(CS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCC)C(=O)N(C)[C@H](CC(=O)O)C(=O)N(C)[C@@H](Cc1ccccc1)C(=O)O
Standard InChI: InChI=1S/C89H132N12O28S/c1-5-7-31-66(82(113)93-56-76(104)95-70(52-63-55-92-65-33-27-26-30-64(63)65)84(115)98-67(32-8-6-2)86(117)100(3)72(54-81(111)112)87(118)101(4)73(89(121)122)51-60-28-22-21-23-29-60)97-83(114)69(50-61-36-38-62(39-37-61)59-130(123,124)125)99-85(116)71(53-80(109)110)96-78(106)58-129-49-47-127-45-43-91-77(105)57-128-48-46-126-44-42-90-74(102)41-40-68(88(119)120)94-75(103)34-24-19-17-15-13-11-9-10-12-14-16-18-20-25-35-79(107)108/h21-23,26-30,33,36-39,55,66-73,92H,5-20,24-25,31-32,34-35,40-54,56-59H2,1-4H3,(H,90,102)(H,91,105)(H,93,113)(H,94,103)(H,95,104)(H,96,106)(H,97,114)(H,98,115)(H,99,116)(H,107,108)(H,109,110)(H,111,112)(H,119,120)(H,121,122)(H,123,124,125)/t66-,67-,68-,69-,70-,71-,72+,73-/m0/s1
Standard InChI Key: POBSWGXKSRFIPJ-ATACWSBSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1850.16 | Molecular Weight (Monoisotopic): 1848.8995 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):